Roche Pharmaceuticals announced on April 30 that China's National Drug Administration officially approved the ophthalmologic injection of the bispecific antibody Vabysmo (generic name: farizimab) to treat macular oedema secondary to retinal branch vein occlusion (BRVO). This is the third indication Luo Shijia has been approved in China after diabetic macular edema (DME) and neovasculatory (wet) age-related macular degeneration (NaMD).
罗氏眼科双抗药物法瑞西单抗在华获批
Roche ophthalmologic dual antibody farazimab approved in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.